MG
SRPT icon

Mather Group’s Sarepta Therapeutics SRPT Stock Holding History

Mather Group’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-213
Closed -$13.6K – 1581
2025
Q1 		$13.6K Hold
213
– – ﹤0.01% 1182
2024
Q4 		$25.9K Hold
213
– – ﹤0.01% 1019
2024
Q3 		$26.6K Sell
213
-35
-14% -$4.84K ﹤0.01% 1007
2024
Q2 		$32.1K Buy
248
+35
+16% +$4.5K ﹤0.01% 1127
2024
Q1 		$20.5K Buy
+213
New +$26.1K ﹤0.01% 1057

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Mather Group's SRPT Position: Q2 2025 in Review

Mather Group sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 213 shares — an estimated $13.6K sold.

Mather Group first reported a position in SRPT in Q1 2024 and held it in 5 quarters. The position peaked at $32.1K in Q2 2024. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Mather Group reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Mather Group sold 213 Sarepta Therapeutics shares in Q2 2025, an estimated $13.6K.
  • Mather Group first reported a position in Sarepta Therapeutics in Q1 2024 and held it in 5 quarters.
  • Mather Group's Sarepta Therapeutics position peaked at $32.1K in Q2 2024.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Mather Group's 13F filing for Q2 2025, filed 15 Jul 2025.